Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report

Abstract Background Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 admin...

Full description

Bibliographic Details
Main Authors: Chung Young Kim, Namju Kim, Ho-Kyung Choung, Sang In Khwarg
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12885-019-5986-5
_version_ 1819019352644517888
author Chung Young Kim
Namju Kim
Ho-Kyung Choung
Sang In Khwarg
author_facet Chung Young Kim
Namju Kim
Ho-Kyung Choung
Sang In Khwarg
author_sort Chung Young Kim
collection DOAJ
description Abstract Background Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid. Case presentation A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes. Conclusion T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid.
first_indexed 2024-12-21T03:33:57Z
format Article
id doaj.art-7d52fcd6b20747418ca1d38373e89cec
institution Directory Open Access Journal
issn 1471-2407
language English
last_indexed 2024-12-21T03:33:57Z
publishDate 2019-08-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj.art-7d52fcd6b20747418ca1d38373e89cec2022-12-21T19:17:23ZengBMCBMC Cancer1471-24072019-08-011911410.1186/s12885-019-5986-5Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case reportChung Young Kim0Namju Kim1Ho-Kyung Choung2Sang In Khwarg3Department of Ophthalmology, College of Medicine, Seoul National UniversityDepartment of Ophthalmology, College of Medicine, Seoul National UniversityDepartment of Ophthalmology, College of Medicine, Seoul National UniversityDepartment of Ophthalmology, College of Medicine, Seoul National UniversityAbstract Background Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid. Case presentation A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes. Conclusion T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid.http://link.springer.com/article/10.1186/s12885-019-5986-5Trastuzumab emtansineKadcylaBreast cancerNasolacrimal duct stenosisEpiphora
spellingShingle Chung Young Kim
Namju Kim
Ho-Kyung Choung
Sang In Khwarg
Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
BMC Cancer
Trastuzumab emtansine
Kadcyla
Breast cancer
Nasolacrimal duct stenosis
Epiphora
title Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
title_full Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
title_fullStr Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
title_full_unstemmed Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
title_short Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
title_sort lacrimal drainage system stenosis associated with trastuzumab emtansine kadcyla r t dm1 administration a case report
topic Trastuzumab emtansine
Kadcyla
Breast cancer
Nasolacrimal duct stenosis
Epiphora
url http://link.springer.com/article/10.1186/s12885-019-5986-5
work_keys_str_mv AT chungyoungkim lacrimaldrainagesystemstenosisassociatedwithtrastuzumabemtansinekadcylatdm1administrationacasereport
AT namjukim lacrimaldrainagesystemstenosisassociatedwithtrastuzumabemtansinekadcylatdm1administrationacasereport
AT hokyungchoung lacrimaldrainagesystemstenosisassociatedwithtrastuzumabemtansinekadcylatdm1administrationacasereport
AT sanginkhwarg lacrimaldrainagesystemstenosisassociatedwithtrastuzumabemtansinekadcylatdm1administrationacasereport